ClinicalTrials.gg
Status unknownNCT04461262Updated Dec 28, 2022

The Impact Of A Catheter Coating On Clinical Bacteriuria

An interventional study of Camstent Coated Catheter and Standard Care in Bacteriuria, sponsored by Camstent Ltd.. Status unknown at 4 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-28.

Sponsored by Camstent Ltd. · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
272
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A prospective multicentre randomized study to assess the impact of a catheter coating on clinical bacteriuria when compared to an uncoated foley catheter.

Each participant will take part in the trial from the time the participant signs the informed consent form (ICF).

After the screening visit, the participants will be randomized to either a coated catheter or an uncoated catheter. Participants will be assigned to receive trial treatment until the catheter has been removed as per standard hospital guidelines, investigator's decision to withdraw the subject, noncompliance with trial treatment or procedures, unacceptable adverse event, or participant withdraws consent.

During the trial urine samples will be taken form the catheter port, temperature will be taken, and participants and healthcare providers will be asked to complete questionnaires.

02

Conditions studied

  • Bacteriuria

Browse trials for

03

In context

Bacteriuria

51 studies on the registry are indexed under Bacteriuria; 3 are open to participants now.

This study's planned enrollment of 272 is above the median of 100 across 37 interventional studies indexed under Bacteriuria.

Browse Bacteriuria studies →

Lead sponsor

Camstent Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Require insertion or exchange of a catheter as a component of their routine clinical care as per hospital guidelines
  2. Patients aged 18+ years will be eligible for the study.
  3. Patient understands and is willing to participate in the study and is able to comply with study procedures and visits.

Exclusion criteria

Exclusion Criteria:

  1. Patients that have or recently (within 3 weeks) had a urinary catheter and displays symptoms of current urinary tract infection.
  2. Pregnant or Breastfeeding.
  3. Patients with a potentially conditions ()
  4. Has a known silicone allergy or sensitivity
  5. Use of drug or device within four weeks prior to study entry that may interfere with this study.
  6. Any medication deemed by the Investigator to potentially interfere with the study treatment
  7. Participation in any other clinical study.
  8. Has a known bloodstream infection or an infection that requires prolonged antibiotic therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
272 participants (estimated)

Study arms

  • Experimental
    Camstent Coated Catheter

    The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked

    Device: Camstent Coated Catheter

  • Other
    Standard Care

    Foley catheter, uncoated

    Device: Standard Care

Interventions

  • DeviceCamstent Coated Catheter

    The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed. The device is CE marked

    Also known as: Standard Care

  • DeviceStandard Care

    Uncoated Foley catheter

06

What researchers measure

Primary outcomes

  1. Change in the number of days in which bacterial concentrations are greater than 10^5 CFU/mL in coated catheters, as compared to uncoated control catheters

    Time frame: 1 Year

Secondary outcomes

  1. Change in the number of cases experiencing Symptomatic Bacteriuria (CAUTI) coated catheters vs. uncoated controls

    Time frame: 1 Year

  2. Change in the number of cases receiving prophylactic or therapeutic Antibiotics during catheter use in coated catheters vs. uncoated controls

    Time frame: 1 Year

  3. Patient Reported Outcomes (PRO)

    EQ-5D-5L questionnaire will be given to participants as well as a questionnaire asking participants on their experience using the catheter

    Time frame: 1 Year

07

Study locations

4 of 4 sites recruiting
  • Stoke Mandeville Hospital
    Buckingham, United Kingdom
    Recruiting
    • Maurizo Belci · Principal investigator
  • Addenbrookes Hospital
    Cambridge, United Kingdom
    Recruiting
    • Suzanne Biers · Principal investigator
  • Royal National Orthopaedic Hospital
    London, United Kingdom
    Recruiting
  • Norfolk & Norwich University Hospital
    Norwich, United Kingdom
    Recruiting
    • Mark Rochester · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04461262
Lead sponsor
Camstent Ltd.
Responsible party
Sponsor
First posted
Jul 8, 2020
Start date
Apr 27, 2021
Primary completion
Sep 2024 (estimated)
Completion
Oct 2024 (estimated)
Last update
Dec 28, 2022

Study contacts

Prital Patel
Contact
prital.patel@camstent.com
+447825757008
Prital Patel
study director · Camstent Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion